Edwards Lifesciences Corp
NYSE:EW
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
67.07
86.85
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one
EW
stock under the Base Case scenario is
61.35
USD.
Compared to the current market price of 86.85 USD,
Edwards Lifesciences Corp
is
Overvalued by 29%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for Edwards Lifesciences Corp.
| US |
|
Abbott Laboratories
NYSE:ABT
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
|
| US |
|
GE Healthcare Technologies Inc
NASDAQ:GEHC
|
|
| US |
|
Resmed Inc
NYSE:RMD
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Edwards Lifesciences depends heavily on its TAVR franchise, making any slowdown in procedural volumes or tighter site-of-service regulations a significant risk to its top line growth.
Aggressive competition from Medtronic and Boston Scientific in transcatheter valve solutions may compress Edwards’ pricing power and limit future market share gains in key geographies.
Heightened R&D spending and lengthy regulatory timelines for next-generation valve therapies could weigh on margins if newer products fail to gain approval or widespread adoption.
Edwards Lifesciences holds a leadership position in TAVR technology, particularly with its SAPIEN platform, which remains the gold standard for many heart centers worldwide and drives robust revenue growth.
Their expanding pipeline of transcatheter mitral and tricuspid repair devices positions the company to capitalize on a growing structural heart market beyond aortic valve replacement.
Strong clinical data and consistent investment in physician education support brand loyalty, ensuring Hospitals and cardiologists continue to prefer Edwards’ valves and monitoring systems.
Revenue & Expenses Breakdown
Edwards Lifesciences Corp
Balance Sheet Decomposition
Edwards Lifesciences Corp
| Current Assets | 6.4B |
| Cash & Short-Term Investments | 3.8B |
| Receivables | 892.8m |
| Other Current Assets | 1.6B |
| Non-Current Assets | 6.9B |
| Long-Term Investments | 274.7m |
| PP&E | 1.8B |
| Intangibles | 2.9B |
| Other Non-Current Assets | 1.9B |
| Current Liabilities | 1.6B |
| Accounts Payable | 282.6m |
| Accrued Liabilities | 969.4m |
| Other Current Liabilities | 336m |
| Non-Current Liabilities | 1.5B |
| Long-Term Debt | 598.2m |
| Other Non-Current Liabilities | 881m |
Free Cash Flow Analysis
Edwards Lifesciences Corp
| USD | |
| Free Cash Flow | USD |
Earnings Waterfall
Edwards Lifesciences Corp
|
Revenue
|
5.9B
USD
|
|
Cost of Revenue
|
-1.3B
USD
|
|
Gross Profit
|
4.6B
USD
|
|
Operating Expenses
|
-3B
USD
|
|
Operating Income
|
1.6B
USD
|
|
Other Expenses
|
-263.8m
USD
|
|
Net Income
|
1.4B
USD
|
EW Profitability Score
Profitability Due Diligence
Edwards Lifesciences Corp's profitability score is 60/100. The higher the profitability score, the more profitable the company is.
Score
Edwards Lifesciences Corp's profitability score is 60/100. The higher the profitability score, the more profitable the company is.
EW Solvency Score
Solvency Due Diligence
Edwards Lifesciences Corp's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Score
Edwards Lifesciences Corp's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
EW Price Targets Summary
Edwards Lifesciences Corp
According to Wall Street analysts, the average 1-year price target for
EW
is 97.12 USD
with a low forecast of 72.72 USD and a high forecast of 110.25 USD.
Dividends
Current shareholder yield for
EW is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
EW
stock under the Base Case scenario is
61.35
USD.
Compared to the current market price of 86.85 USD,
Edwards Lifesciences Corp
is
Overvalued by 29%.